Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)

Stokke, Jamie; Tann, Annabelle; El‐Mallawany, Nader Kim; Oschlies, Ilske

doi:10.1016/j.beha.2023.101448

Cited by 2 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subcutaneous panniculitis like T-cell lymphoma (SPTCL) is a rare subtype of peripheral T cell lymphoma (PTCL), and caused by panniculitis like cytotoxicity α-β T cells infiltrate subcutaneous tissues. [ 1 ] The incidence rate of SPTCL is extremely low, accounting for <1% of non-Hodgkin lymphoma. [ 2 ] SPTCL usually occurs in young adults, with an average age of 36 years.…”

Section: Introductionmentioning

confidence: 99%

Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT

Zhang,

et al. 2023

Medicine

View full text Add to dashboard Cite

Rationale: Subcutaneous panniculitis like T-cell lymphoma (SPTCL) is a rare primary cutaneous lymphoma that belongs to peripheral T cell lymphomas, of which the overall prognosis is poor. Chidamide, a deacetylase inhibitor, has been approved for the treatment of peripheral T cell lymphomas. However, due to the rare occurrence of SPTCL, it is currently unknown whether Chidamide is effective for all SPTCL patients and whether there are molecular markers that can predict its therapeutic effect on SPTCL. Patient concerns and diagnoses: The patient was a sixteen-year-old male and underwent subcutaneous nodule biopsy which showed SPTCL. Next-generation sequencing revealed AT-rich interaction domain 1A (ARID1A) mutation, and positron emission tomography/computed tomography showed scattered subcutaneous fluorodeoxyglucose metabolic lesions throughout the body. Interventions and outcomes: During the first 3 CHOP (cyclophosphamide, doxorubicin, vindesine, and prednisone) treatment, the patient relapsed again after remission, and the successive addition of methotrexate and cyclosporine did not make the patient relapsing again. Then, after adding Chidamide to the last 3 CHOP treatment, the patient was relieved again. The patient underwent autologous hematopoietic stem cell transplantation (auto-HSCT) after completing a total of 8 cycles of chemotherapy, and continued maintenance therapy with Chidamide after auto-HSCT. Currently, the patient has been in continuous remission for 35 months. Lessons subsections: This case is the first report of a refractory/recurrent SPTCL with ARID1A mutation treated with Chidamide. The treatment of Chidamide on the basis of CHOP plus auto-HSCT therapy achieved good results, suggesting that ARID1A may act as a molecular marker to predict the therapeutic effect of Chidamide on SPTCL patients, which helps to improve the precision of SPTCL treatment and the overall prognosis of SPTCL patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT

Zhang,

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

Pediatric Cutaneous T‐Cell Neoplasms: Clinical and Pathological Features, Updated Classifications, and Critical Differential Diagnoses

Cheng,

Wistinghausen,

Kirkorian

2024

Pediatric Dermatology

View full text Add to dashboard Cite

Cutaneous T‐cell lymphoid neoplasms in childhood are exceedingly rare, presenting with a wide spectrum of clinical presentation and outcomes. Due to numerous clinical and pathological mimics, an integrated evaluation of clinical, histopathological, immunohistochemical, and molecular findings is critical for a diagnosis. Here, we review the clinical and pathological features, updated classifications, and critical differential diagnoses of cutaneous T‐cell lymphoid neoplasms in children.

show abstract

Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)

Cited by 2 publications

References 88 publications

Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT

Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT

Pediatric Cutaneous T‐Cell Neoplasms: Clinical and Pathological Features, Updated Classifications, and Critical Differential Diagnoses

Contact Info

Product

Resources

About